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IntroductIon
Multiple	 sclerosis	 is	 an	 inflammatory	demyelinating	
disorder	of	CNS,	that	may	appear	with	a	variety	of	dif-
ferent	 clinical	 presentations	 and	 laboratory	findings.	
Tumefactive	MS	is	a	type	of	MS	which	is	character-
ized	by	 the	presence	of	at	 least	one	 lesion	≥	2cm	in	
diameter1.	Radiologically,	it	presents	as	single	or	mul-
tiple	contrast-enhanced	lesions,	with	co-existing	mass	
effect	 and	edema	≥	3mm.	The	presence	of	cystic	or	
necrotic	areas	is	also	possible2.
The	contribution	of	modern	MRI	techniques	in	the	
diagnosis	 and	 differential	 diagnosis	 of	 tumefactive	
MS	is	strongly	supported	by	the	scientific	world.
cASE rEPortS
Case 1: A	17-year-old	male	was	referred	to	AHEPA	
hospital	 emergency	 department,	 with	 left	 hemipare-
sis	 and	 dysarthria.	 Two	 similar	 transitory	 episodes	
were	 also	 revealed	 in	 his	 medical	 history.	 Cerebro-
spinal	fluid	analysis	revealed	IgG	oligoclonal	bands,	
therefore	 indicating	 possible	MS.	The	MRI	 showed	
a	mass	 in	 the	 right	 semi-oval	 center	 with	mediocre	
edema	(Figure	1a).	The	patient	had	a	rapid	response	
to	the	conservative	treatment	with	high	doses	of	ste-
roids,	which	was	confirmed	by	the	radiological	retest	
(Figure	1b).	Two	years	 later,	 he	was	admitted	again	
in	 the	 ER,	 with	 status	 epilepticus,	 right	 hemipare-
sis	 and	walk	 disorders.	The	Computed	Tomography	
(CT)	 scan	 only	 revealed	 the	 first	 lesion	 in	 the	 right	
hemisphere	(Figure	1c).	The	MRI	confirmed	a	second	
tumefactive	 lesion	 in	 the	 opposite	 hemisphere,	with	
spotted	enhancement,	while	the	first	lesion	showed	no	
enhancement	(Figure	1d).	The	patient	fully	recovered	
after	treatment	with	steroids.
Case 2:	A	65-year-old	female	was	admitted	to	our	
hospital	with	acute	right	hemianopsia.	The	CT	carried	
out	a	few	hours	afterwards	(Figure	2a)	,	as	well	as	the	
MRI	carried	out	a	few	days	later,	showed	a	left	tem-
poral-occipital	mass	in	the	cerebral	parenchyma	with	
non-homogeneous,	 peripheral,	 annular	 enhancement	
(open	ring	sign)	and	mediocre	circumcentral	edema.	
However,	because	of	 the	negative	 laboratory	exami-
nations	and	the	advanced	age	of	the	patient,	an	intra-
cranial	mass	was	thought	to	be	the	possible	diagnosis.	
As	a	result,	the	mass	was	surgically	removed	(Figure	
2c).	 However,	 the	 histological	 examination	 showed	
perivascular	 infiltration	by	histiocells	and	demyelin-
ation.	Two	years	later,	the	patient	was	admitted	with	
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left	 hemianopsia.	 The	 CT	 and	 the	MRI	 (Figure	 2d,	
e)	showed	a	second	mass	in	the	opposite	hemisphere	
with	 the	same	characteristics	(open	ring	sign)	as	 the	
first	lesion.	The	findings	of	MR	spectroscopy	(Figure	
3)	 spoke	 in	 favor	 of	MS;	 therefore	 the	 patient	 was	
treated	conservatively	with	steroids	and	showed	satis-
factory	clinical	improvement,	as	well	as	restriction	of	
pathological	enhancement	in	the	retest	(Figure	4).	
Figure 1.	a.	Axial	T2-weighted	 image	revealed	a	mass	 in	
the	 right	 semioval	 centre	 with	mediocre	 edema.	 b.	Axial	
T1-weighted	 image	 showed	 important	 restriction	 of	 the	
damage.	c.	Axial	CT	image	showed	hypointense	lesion	left	
respectively	with	 the	 first	 lesion	 d.The	MRI	 confirmed	 a	
second	 tumefactive	 lesion	 in	 opposite	 hemisphere,	which	
showed	spotted	enhancement,	while	the	first	lesion	did	not	
show	any	enhancement.
Figure 2. a.	Axial	CT	image	revealed	a	hypodense	left	tem-
poral-occipital	mass	 in	 the	 cerebral	 parenchyma.	b.	Axial	
contrast-enhanced	T1-	weighted	image	revealed	a	left	tem-
poral-occipital	mass	in	the	cerebral	parenchyma	with	non-
homogeneous,	peripheral	annular	enhancement	(open	ring	
sign).	c.	Axial	contrastenhanced	T1-	weighted	image	after	
the	surgical	removal	of	the	mass	where	appears	the	crani-
otomy	and	the	gliosis	of	brain	respectively.	d,	e.	Axial	CT	
image	 and	 coronal	 contrastenhanced	T1-	weighted	 image	
revealed	 a	 second	mass	 in	 opposite	 hemisphere	 with	 the	
same	characteristics	(open	ring	sign)	of	the	first	lesion.
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dIScuSSIon
Advanced	MRI	techniques	have	been	established	for	
better	neuroimmaging	evaluation	in	MS.	In	the	mag-
netization	 transfer	 (MTR),	 which	 is	 related	 to	 the	
phenomenon	of	transport	of	magnetization,	demyelin-
ation	represents	a	progressive	reduction	of	ratio	from	
the	periphery	to	the	centre	of	the	lesion3-5.	In	diffusion	
MRI,	MS	lesions	appear	with	increased	Apparent	Dif-
fusion	Coeficient	(ADC)	reception,	in	contrast	to	cere-
bral	abscess	where	reduction	of	ADC	is	observed3.	In	
perfusion	MRI,	MS	lesions	show	neither	increase	nor	
decrease	of	rCBF,	in	contrast	to	cerebral	tumors	where	
increase	of	rCBF	is	observed3,6.	In	MR	spectroscopy,	a	
reduction	of	NAA,	Cr,	β,	γ-Glx	and	detection	of	LAC,	
CHO	and	lipids	during	the	acute	phase	of	MS,	have	
been	 reported.	 On	 the	 contrary,	 during	 the	 chronic	
phase	of	MS	there	is	an	increase	of	NAA,	Cr	and	dis-
appearance	of	LAC	and	lipids3,5,7-9.	In	our	study,	MR	
spectroscopy	based	on	measurements	of	metabolites	β	
and	γ-Glx	was	proven	helpful	in	the	differential	diag-
nosis	of	MS9.	Indeed,	these	markers	increase	in	case	
of	tumefactive	MS,	but	not	in	aggressive	intracranial	
masses	(Figure	5).
Three	 major	 observations	 were	 evident	 in	 our	
study.	The	first	was	related	to	the	peripheral,	non-ho-
mogenous,	annular	enhancement	of	lesion,	character-
ized	as	“open	ring	sign”,	which	is	observed	in	tume-
factive	 MS10.	 The	 enhancement	 is	 related	 to	 blood	
brain	barrier	breakdown.	Nevertheless,	experimental	
data	also	report	enhancement	of	the	lesion	even	with	
intact	blood	brain	barrier	due	to	macrophage	infiltra-
tion2.	The	second	observation	concerns	the	histopath-
ological	 findings;	 reactive	 astrocytosis	with	 atypical	
mitotic	 characteristics,	 foamy	 macrophages	 (myelin	
breakdown	products)	and	chronic	perivascular	cellu-
lar	 infiltration	cause	major	difficulties	 in	differential	
Figure 3.	MR	Spectroscopy	of	the	patient	which	confirmed	
the	diagnosis.
Figure 4. Axial	MRI	images	showed	restriction	of	patholog-
ical	enhancement	of	lesion	after	dispensation	of steroids.
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diagnosis	 from	glioma11.	The	 third	 observation	 con-
cerns	the	progress	of	the	underlying	pathology	and	the	
correspondent	 clinical	 impact.	 Evidently	 despite	 the	
radiological	features	of	the	lesion,	and	the	possibility	
of	malignancy,	 it	would	be	preferable	 to	perform	an	
intensive	follow	up	with	neuroimmaging	for	the	safe-
ty	of	 the	final	diagnosis	 rather	 than	proceeding	with	
the	 treatment	 such	 as	operation	or	 irradiation	of	 the	
lesion.	In	addition,	in	case	of	demyelinating	disorders	
the	response	to	steroid	therapy	is	usually	satisfactory.	
The	 inflammatory	 demyelinating	 brain	 disorders	
often	 imitate	 intracranial	 masses.	 The	 tumefactive	
MS	 should	 be	mainly	 differentiated	 from	 tumors	 as	
glioma,	 astrocytoma	 and	 lymphoma,	 from	 other	 in-
flammatory	demyelinating	disorders	as	acute	dissemi-
nated	encephalomyelitis	 (ADEM)	and	 from	cerebral	
abscesses11,12.	Certain	 laboratory	findings,	 coexisting	
lesions	 in	neuroradiology	examinations	 (eg.	cervical	
spinal	cord)	and	rapid	response	to	cortisone	favor	tu-
mefactive	MS.	In	the	cases	presented	here,	the	distinct	
clinical	and	radiological	presentations	of	the	same	dis-
ease	in	two	different	individuals,	were	identified.	The	
first	 patient	was	 successfully	 treated	 conservatively,	
on	the	contrary	to	the	second	one	who	underwent	un-
necessary	 surgical	 operation.	 In	 the	 second	 case	 the	
correct	diagnosis	was	made	later	with	the	contribution	
of	MR	spectroscopy	and	the	patient	was	then	treated	
appropriately.	 The	 intracranial	 masses	 constitute	 an	
important	medical	problem.	The	role	of	modern	imag-
ing	should	not	only	be	limited	in	anatomic	details.	The	
advanced	MRI	techniques	allow	us	to	investigate	brain	
function;	perfusion	MRI	gives	important	information	
about	blood	cerebral	flow	(rCBF);	MR	spectroscopy	
helps	us	measure	various	brain	metabolites.	
concLuSIon
In	 the	differential	diagnosis	of	 tumefactive	brain	 le-
sions,	 the	 tumefactive	MS	should	always	be	consid-
ered.	 Moreover,	 the	 advanced	 imaging	 techniques	
promise	precise	diagnostic	approach,	in	order	to	avoid	
unnecessary	interventional	procedures	for	the	final	di-
agnosis	and	differential	diagnosis.
Abbreviations:
ADC: Apparent Diffusion Coeficient
ADEM: acute disseminated encephalomyelitis
CHO: choline
Cr: creatine
LAC: lactate
MRI: Magnetic Resonance Imaging
MS: multiple sclerosis
MTR: magnetization transfer 
NAA: N-acetylaspartate
rCBF: blood cerebral flow 
β, γ-Glx: glutamate/glutamine
Figure 5. a.	Axial	 T1-weighted	 post-contrast	 MR	 image	
shows	 a	 small	 ring-enhancing	 lesion	 in	 the	 genu	 of	 the	
right	 internal	capsule	 (arrow)	and	a	barely	perceptible	 le-
sion	in	the	left	globus	pallidus	(arrowhead).	Multiple	addi-
tional	similar	small	ring-enhancing	lesions	were	identified	
throughout	the	brain	parenchyma.	b.	Voxel	localization	for	
proton	MR	spectroscopy	of	the	right	internal	capsule	lesion.	
c.	MR	spectroscopy	of	the	right	internal	capsule	lesion	dem-
onstrates	marked	elevation	of	the	β,γ-Glx	peaks	(double	ar-
rows)	compared	with	creatine	(peak	height	 ratio	1.1	[nor-
mal	 less	 than	 0.5])	 compatible	with	 tumefactive	multiple	
sclerosis.	There	is	also	mild	decrease	of	N-acetylaspartate	
and	probable	mild	presence	of	lactate.
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ΠΕΡΙΛΗΨΗ:	Ως	ογκόμορφη	ορίζεται	η	πολλαπλή	σκλήρυνση	που	χαρακτηρίζεται	από	την	παρουσία	μίας	τουλάχιστον	
βλάβης,	διαμέτρου	≥	2	εκ.,	με	συνοδό	φαινόμενο	μάζας	ή	οίδημα	οποιουδήποτε	βαθμού.	Στην	εργασία	γίνεται	εκτενής	βιβλι-
ογραφική	ανασκόπηση	στις	νεότερες	MRI	τεχνικές	με	τις	οποίες	μελετάται	η	ογκόμορφη	πολλαπλή	σκλήρυνση	και	τίθεται	η	
διάγνωσή	της.	Αναφέρεται,	ακόμη,	το	εύρος	της	διαφορικής	διάγνωσης	της	πάθησης	από	άλλες	χωροκατακτικές	εξεργασίες	
του	εγκεφάλου.	Παρουσιάζονται,	επίσης,	δύο	περιστατικά	ασθενών	με	ογκόμορφη	πολλαπλή	σκλήρυνση.	Συμπερασματικά,	
καταλήγουμε	στο	γεγονός	ότι	πρέπει	πάντα	να	διερευνάται	η	περίπτωση	της	ογκόμορφης	πολλαπλής	σκλήρυνσης	σε	κάθε	
ασθενή	με	απεικονιστικά	ευρήματα	χωροκατακτικής	μάζας	του	εγκεφάλου	ώστε	να	αποφεύγονται	άσκοπες	επεμβατικές	
μέθοδοι	για	την	τελική	διάγνωση	και	διαφοροδιάγνωση.
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